SS-31 / elamipretide
A mitochondrial-targeted peptide with one narrow approved product indication.
The short version
- Why people discuss it
- AxonRep’s community research identifies broad interest in SS-31 for mitochondrial function, energy, recovery and aging. The approved evidence is much narrower: Forzinity is indicated to improve muscle strength in people with Barth syndrome weighing at least 30 kg.
- What it is
- SS-31 is the research name for elamipretide. Forzinity is a specific elamipretide hydrochloride formulation; an internet product labeled “SS-31” is not automatically equivalent to the approved drug.
- Biggest caution
- The FDA label reports frequent injection-site reactions and warns about hypersensitivity. Approval used an intermediate endpoint under accelerated approval and does not establish anti-aging, recovery or general energy benefits.
- Stack context
- MOTS-c and NAD+ appear beside SS-31 in community mitochondrial stacks. The Forzinity label does not validate those combinations or authorize transferring its dose to another product.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Source agreement describes reported practice, not clinical validation.
Forzinity subcutaneous injection
Approved label · Product-specific- Amount
- 40 mg
- Frequency
- Once daily
- Duration / phase
- Product-specific ongoing treatment
Forzinity label only: Barth syndrome in patients weighing at least 30 kg, with label-directed modification in adults with severe renal impairment. Not a generic SS-31 wellness regimen. Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-27SS-31 community products — subcutaneous
Community reference · Not clinical guidance- Amount
- 5 mg initially; 10 mg in the source’s later phase
- Frequency
- Once daily
- Duration / phase
- 8–12 weeks
One publisher’s experimental community pattern; Peptidepedia also describes 10–20 mg/day and an 8-week-on/4-week-off example. These are not the Forzinity label or established healthy-person dosing.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
5 mg then 10 mg SC daily, 8–12 weeks; advanced 15–20 mg; separately acknowledges Forzinity 40 mg.
- Peptidepedia — saved source reviewed September 27, 2026
Community 5 mg start, 10–20 mg moderate daily, sometimes 20–40 mg; 8 weeks on/4 off example.
Evidence & sources · Approved product label
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- Current Forzinity prescribing informationProduct label · Checked 2026-09-27
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27